Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author de Bruin-Weller, Marjolein
- dc.contributor.author Pink, Andrew E.
- dc.contributor.author Patrizi, Annalisa
- dc.contributor.author Giménez Arnau, Anna Maria
- dc.contributor.author Agner, Tove
- dc.contributor.author Roquet-Gravy, Pierre-Paul
- dc.contributor.author Ferrucci, Silvia M.
- dc.contributor.author Arenberger, Petr
- dc.contributor.author Svensson, Ake
- dc.contributor.author Schuttelaar, Marie L. A.
- dc.contributor.author Nosbaum, Audrey
- dc.contributor.author Jayawardena, Shyamalie
- dc.contributor.author Rizova, Elena
- dc.contributor.author Ardeleanu, Marius
- dc.contributor.author Eckert, Laurent
- dc.contributor.author Ozturk, Zafer E.
- dc.date.accessioned 2021-10-22T07:31:22Z
- dc.date.available 2021-10-22T07:31:22Z
- dc.date.issued 2021
- dc.description.abstract Background: Insights into the real-world treatment paradigm and long-term burden of atopic dermatitis (AD) are needed to inform clinical and health policy decisions. Methods: The prospective, observational EUROSTAD study enrolled adults with moderate-to-severe AD starting or switching systemic therapy (51 sites in 10 European countries). We report the baseline characteristics, treatment patterns, and outcomes of these patients using descriptive statistics. Results: A 12-month enrollment period of EUROSTAD was completed and 308 patients were enrolled: average age 37 years, AD duration 25 years, 43% were female. Most patients reported use of systemic therapy (93%) and ≥1 atopic comorbidity (82%). Mean [standard deviation] disease severity/burden measures were high: Investigator's Global Assessment (3.1 [0.8]), Eczema Area and Severity Index (16.2 [10.9]), Peak Pruritus Numerical Rating Scale (5.5 [2.5]), sleep impairment Visual Analog Scale (49.8 [31.6]) scores, and time lost from work (4.1 [13.7] days/year) or usual activities (16.8 [38.7] days/year). Most patients showed borderline or clinical levels of anxiety (59%) and/or depression (63%) using the Hospital Anxiety and Depression Scale. Conclusions: Adults with moderate-to-severe AD starting/switching systemic treatment enrolled in EUROSTAD have a high burden of longstanding disease despite continuous use of topical drugs, emollients, and systemic therapies.
- dc.format.mimetype application/pdf
- dc.identifier.citation Bruin-Weller M, Pink AE, Patrizi A, Gimenez-Arnau AM, Agner T, Roquet-Gravy PP, et al. Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. J Dermatolog Treat. 2021 Mar;32(2):164-73. DOI: 10.1080/09546634.2020.1866741
- dc.identifier.doi http://dx.doi.org/10.1080/09546634.2020.1866741
- dc.identifier.issn 0954-6634
- dc.identifier.uri http://hdl.handle.net/10230/48760
- dc.language.iso eng
- dc.publisher Informa Healthcare
- dc.rights This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.subject.keyword Atopic dermatitis
- dc.subject.keyword Patient-reported outcomes
- dc.subject.keyword Quality of life
- dc.subject.keyword Systemic therapy
- dc.title Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion